Bright Minds Biosciences Inc(DRUG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.08 | Insider Own | 23.39% | Shs Outstand | 9.9M | Perf Week | 7.59% |
| Market Cap | 0.56B | Forward P/E | - | EPS next Y | -133.81% | Insider Trans | -4.52% | Shs Float | 7.6M | Perf Month | 13.79% |
| Enterprise Value | 0.34B | PEG | - | EPS next Q | -1.15 | Inst Own | 83.47% | Short Float | 10.98% | Perf Quarter | -22.62% |
| Income | -0.02B | P/S | - | EPS this Y | -108.93% | Inst Trans | 2.99% | Short Ratio | 6.24 | Perf Half Y | -35.54% |
| Sales | 0.00B | P/B | 2.58 | EPS next 5Y | - | ROA | -13.8% | Short Interest | 0.83M | Perf YTD | -27.36% |
| Book/sh | 21.99 | P/C | 2.58 | EPS past 3/5Y | 35.51% -35.46% | ROE | -13.93% | 52W High | -54.19% ($123.75) | Perf Year | 5.1% |
| Cash/sh | 22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -8.18% | 52W Low | 20.03% ($47.23) | Perf 3Y | 3949.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -120.28% | Gross Margin | - | Volatility(W/M) | 5.51% 7.14% | Perf 5Y | 59.24% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 121.97 | EPS Q/Q | 67.03% | Profit Margin | - | RSI (14) | 53.9 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 121.97 | Sales Q/Q | - | SMA20 | 7.97% ($52.51) | Beta | -4.93 | Target Price | $149.12 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/17 | SMA50 | -4.97% ($59.65) | Rel Volume | 0.51 | Prev Close | $55.32 |
| Employees | 25 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 86.51% - | SMA200 | -22.81% ($73.44) | Avg Volume(3M) | 0.13M | Price | $56.69 |
| IPO | 2021/3/22 | Option/Short | Yes/Yes | Trades | 1063 | Volume | 67,554 | Change | 2.48% |
🧠 Bright Minds Biosciences (ticker DRUG) is a clinical-stage biotech company developing next-generation therapies for neurological and psychiatric disorders that target serotonin receptors. Its core pipeline includes a serotonin-agonist candidate aimed at drug-resistant epilepsy, and through selective receptor modulation technology, the company is pursuing novel drug candidates designed to overcome the limitations of existing treatments.
Over the past 1 year, on the lower side
54% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
DRUG has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -108.9% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +59.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 83.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #210 of 594 in the industry
Based on market cap of $559M.
STTK#209 Shattuck Labs Inc $574M PER - DRUG#210 Bright Minds Biosciences Inc $559M PER - 
PBYI#211 Puma Biotechnology Inc $544M PER 20.4 
VALN#212 Valneva SE ADR $543M PER - 
ENTX#213 Entera Bio Ltd $543M PER - 
FAQ
What kind of company is DRUG?
DRUG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DRUG?
The market cap of DRUG is approximately $559M, ranking 3,066 within its sector.
What is the 52-week high and low for DRUG?
DRUG has recorded a 52-week high of $123.75 and a low of $47.23.
